Loading…
Reported covered position: GOVERNMENT RELATIONS MANAGER
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Viral Hepatitis Testing Act of 2011
Client: HARM REDUCTION COALITION · Firm: HARM REDUCTION COALITION
Viral Hepatitis Testing Act of 2011- HR 3381 Viral Hepatitis Testing Act of 2011-S. 1809 Authorize appropriations for testing for viral hepatitis.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2015 · second_quarter · 2@
Issues related to the opioid epidemic and their attendant health consequences, including substance use disorder, overdose, infectious disease and neonatal abstinence syndrome.
Viral hepatitis and HIV/AIDS prevention and treatment
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Source: Senate LDA
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2015 · second_quarter · 2T
Issues related to the opioid epidemic and their attendant health consequences, including substance use disorder, overdose, infectious disease and neonatal abstinence syndrome.
Viral hepatitis and HIV/AIDS prevention and treatment
Filing targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2015 · first_quarter · RA
Hepatitis C, Overdose
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2015 · second_quarter · Q2
Viral hepatitis and HIV/AIDS prevention and treatment
Issues related to the opioid epidemic and their attendant health consequences, including substance use disorder, overdose, infectious disease and neonatal abstinence syndrome.
Filing targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2015 · first_quarter · Q1
Issues related to the opioid epidemic and their attendant health consequences, including substance use disorder, overdose, infectious disease and neonatal abstinence syndrome.
Viral hepatitis and HIV/AIDS prevention and treatment
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2014 · fourth_quarter · Q4
Expand access and utilization of naloxone to prevent and treat opioid overdose
Filing targets: HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2014 · third_quarter · Q3
Hepatitis C prevention, testing and treatment.
Opioid overdose prevention measures, including the expanded access of naloxone. Reduce barriers to medication assisted treatment; suboxone/buprenorphine.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2014 · second_quarter · Q2
Overdose prevention education and naloxone distribution The rise in opioids and their impact on treatment capacity The federal funding ban on syringe exchange
Hepatitis C prevention, testing and treatment
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2014 · first_quarter · Q1
Treatment and testing of hepatitis C, and other related health consequences, of the twin opioid epidemics of prescription and nonprescription opioids
Overdose prevention interventions including access and utilization of naloxone
Filing targets: HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2013 · fourth_quarter · Q4
Overdose prevention and education Increasing opioid use, both prescription and nonprescription
Filing targets: HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2013 · third_quarter · Q3
Viral hepatitis testing and treatment access
Overdose prevention Syringe exchange services Addiction treatment access
Filing targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2013 · second_quarter · Q2
Viral hepatitis testing and treatment
Overdose prevention and naloxone access Access to addiction treatment, specifically access to medication assisted treatment Viral hepatitis testing and treatment
Filing targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2013 · first_quarter · Q1
Expansion of naloxone access and utilization to prevent overdose mortality Prescription drug safety Reverse the federal funding ban on syringe exchange services
Viral hepatitis testing and access to treatment Prevention of viral hepatitis infection in injection drug users Treatment of neonatal abstinence syndrome
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2012 · fourth_quarter · Q4
Viral hepatitis testing and treatment access
Overdose prevention - prescription drug safety and access to naloxone Overturn the federal funding ban on syringe exchange services in appropriation bills
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2012 · third_quarter · Q3
Prescription drug abuse and overdose prevention. Access to naloxone. Hepatitis C research, testing and treatment
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2012 · second_quarter · Q2
Prescription drug abuse and overdose prevention. Access to naloxone. Hepatitis C research, testing and treatment
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2012 · second_quarter · Q2
Access to naloxone Opioid overdose prevention Viral Hepatitis Testing Act of 2011 Over turning the federal funding ban on syringe exchange services
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2012 · first_quarter · Q1
Access to Naloxone Opioid overdose prevention Viral Hepatitis Testing Act of 2011 Division of Viral Hepatitis Opposition of the reinstatement of the federal funding ban on syringe exchange services
Filing targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP)
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2011 · fourth_quarter · Q4
Viral Hepatitis Testing Act of 2011- HR 3381 Viral Hepatitis Testing Act of 2011-S. 1809 Authorize appropriations for testing for viral hepatitis.
2012 Consolidated Appropriations Act- fighting the reinstatement of the federal ban on syringe exchange services. Protection of the Prevention and Public Health Fund. Educate members concerned with drug shortages about the lifesaving medication Naloxone which is currently at risk for shortage. Educate the administration about the lifesaving medication naloxone and its need to be included in an overdose prevention strategy.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE
HARM REDUCTION COALITION via HARM REDUCTION COALITION
2011 · fourth_quarter · RR
SYRINGE EXCHANGE, HEPATITIS, GLOBAL HIV/AIDS
SYRINGE EXCHANGE, HEPATITIS, GLOBAL HIV/AIDS
SYRINGE EXCHANGE, HEPATITIS, GLOBAL HIV/AIDS
SYRINGE EXCHANGE, HEPATITIS, GLOBAL HIV/AIDS
SYRINGE EXCHANGE, HEPATITIS, GLOBAL HIV/AIDS
SYRINGE EXCHANGE, HEPATITIS, GLOBAL HIV/AIDS